Pharmaceutics, Volume 16, Issue 12
2024 December - 145 articles
Cover Story: There is a need for new therapies with distinct mechanisms to treat inflammatory bowel disease (IBD). IBD pathophysiology is complex and involves genetic susceptibility, environmental factors, and immune dysfunction. Certain microRNAs (miRNAs), like miR146a, play a role in IBD by regulating gene transcription. miR146a downregulates NF-kB nuclear translocation and inflammation, but its instability challenges therapeutic use. We stabilized miR146a for therapeutic use by conjugating it to cerium oxide nanoparticles (CNPs), which also scavenge free radicals and reduce reactive oxygen species. Furthermore, we have previously demonstrated the preclinical efficacy of intrarectal CNP-miR146a in acute colitis. In this study, we examine the preclinical efficacy of orally administered CNP-miR146a in a more clinically relevant model of chronic T cell-mediated colitis. View this paper - Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
- You may sign up for email alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
